Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.

Annals of neurology - 1 Jan 2018

Hagemann Tracy L, Powers Berit, Mazur Curt, Kim Aneeza, Wheeler Steven, Hung Gene, Swayze Eric, Messing Albee

Abstract excerpt

OBJECTIVE: Alexander disease is a fatal leukodystrophy caused by autosomal dominant gain-of-function mutations in the gene for glial fibrillary acidic protein (GFAP), an intermediate filament protein primarily expressed in astrocytes of the central nervous system. A key feature of pathogenesis is overexpression and accumulation of GFAP, with formation of characteristic cytoplasmic aggregates known as Rosenthal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alexander Disease
Share to Brain Chemistry

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glial Fibrillary Acidic Protein

Share to Hippocampus

Share to Injections, Intraventricular

Share to Neurogenesis

Share to Oligonucleotides, Antisense

Share to Spinal Cord

Source

Open in PubMed Open full text

Identifiers

PMID: 29226998
DOI: 10.1002/ana.25118
PMCID: PMC5876100

Genes

GFAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.PMID 29226998Read ↗

Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.Semantic proximity Read ↗

Antisense therapy in a new rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairmentSemantic proximity Read ↗

Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.Semantic proximity Read ↗

Alexander disease: models, mechanisms, and medicine.Semantic proximity Read ↗

Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes.Semantic proximity Read ↗

Deficits in adult neurogenesis, contextual fear conditioning, and spatial learning in a Gfap mutant mouse model of Alexander disease.Semantic proximity Read ↗

Alexander Disease: A Literature Review for Clinicians.Semantic proximity Read ↗

Elevated GFAP isoform expression promotes protein aggregation and compromises astrocyte function.Semantic proximity Read ↗

Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance.Semantic proximity Read ↗

Synergistic Effects of Glial Fibrillary Acidic Protein Mutation and Overexpression in the Pathogenesis of Alexander Disease.Semantic proximity Read ↗

Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease.Semantic proximity Read ↗

GFAP mutations in Alexander disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.